** Shares of WuXi XDC Cayman Inc 2268.HK, a Chinese antibody drug conjugates research, development and manufacturing services provider, jump 14.5% to HK$56.55, their highest level since debut in November 2023
** Stock marks its biggest intraday pct gain since July 31, 2024 and on track to snap three straight sessions of losses, if current trend continues
** Top pct gainer in healthcare index .HSCIH, which is up 1.2%
** Co expects H1 net profit to increase more than 50% y/y, with revenue up over 60% y/y, due to growth of downstream demand in antibody drug conjugate and broader bioconjugate industry, among others
** Hang Seng Biotech Index .HSHKBIO rises 1.1%, benchmark Hang Seng Index .HSI climbs 0.6%
** YTD, stock up 81.4%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。